Compare BioNano Genomics Inc (BNGO) vs Kaltura Inc (KLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Kaltura Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Kaltura Inc trades at $1.58 (market cap $249.42M). The key difference: Kaltura Inc is far larger — about 18.3× BioNano Genomics Inc's market cap, and Kaltura Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | KLTR | |
|---|---|---|
Market Cap | $13.66M | $249.42M |
Sector | Health | Technology |
52-Week High | $4.92 | $1.89 |
52-Week Low | $1.06 | $1.08 |
Enterprise Value | $16.26M | $261.64M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Kaltura (KLTR) trades at $1.61, down 1.83% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported Q2 2026 earnings that beat expectations, with revenue stable around $181 million and improving net loss margins. Recent news highlights leadership in virtual event platforms and AI technology awards, alongside significant insider selling in August 2026.
The outlook is mixed: analyst consensus leans buy (44.45%) with strong gross margins (72.05%), but persistent net losses and high valuation ratios (EV/EBITDA 336.29) pose risks. Investment opportunity hinges on AI product growth and cost management, while execution risks and cash flow volatility remain concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →
